Clinical trial
Efficacy and Safety Study of Oral BG00012 With Active Reference in…
NCT00451451 · Biogen, Industry · Completed
Key facts
| NCT number | NCT00451451 |
|---|---|
| Title | Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis |
| Official title | A Randomized, Multicenter, Placebo-Controlled and Active Reference (Glatiramer Acetate) Comparison Study to Evaluate the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis |
| Acronym | CONFIRM |
| Lead sponsor | Biogen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Relapsing-Remitting Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | BG00012, Placebo, Glatiramer Acetate |
| Enrollment | 1,417 |
| Start date | Jun 1, 2007 |
| Primary completion | Aug 1, 2011 |
| Completion | Aug 1, 2011 |
| First posted | Mar 23, 2007 |
| Last update posted | Jan 26, 2015 |
| Countries | Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Costa Rica, Croatia, Czechia, Estonia, France, Germany, Greece and 16 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: